Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Artrya Limited ( (AU:AYA) ) has issued an announcement.
Artrya Limited has announced the issuance of 120,761 ordinary shares following the exercise of unlisted incentive securities, while 229,239 unlisted options have lapsed. This movement in securities is part of the company’s ongoing efforts to commercialize its Salix AI-powered cloud platform for coronary artery disease management, which may impact its market positioning by enhancing its capital structure and operational capabilities.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company that focuses on developing AI-powered solutions for the detection and management of coronary artery disease. Their proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in diagnosing patients more accurately and efficiently. The company is engaged in regulatory and commercial activities across key international markets.
Average Trading Volume: 629,441
Technical Sentiment Signal: Buy
Current Market Cap: A$325.2M
See more data about AYA stock on TipRanks’ Stock Analysis page.